Metformin Downregulates the STAT Pathway and Reduces Bone Marrow Fibrosis in Primary Myelofibrosis Patients: Final Results of the Phase II FIBROMET Trial.
Paula de Melo Campos, Kátia Borgia Barbosa Pagnano, Fernanda Soares Niemann, Rubia Isler Mancuso, Fernanda Isabel Della Via, Ada Congrains, Juan Luiz Coelho-Silva, Ângela Condotta Tinoco, Guilherme Rossi Assis-Mendonça, Leandro Luiz Lopes de Freitas and 2 more
Trial report in Hematological oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Juan Luiz Coelho-SilvaDepartment of Medical Imaging, Hematology and Oncology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Ângela Condotta TinocoDepartment of Pathology, Universidade Estadual de Campinas (Unicamp), Sao Paulo, Brazil.
Guilherme Rossi Assis-MendonçaDepartment of Pathology, Universidade Estadual de Campinas (Unicamp), Sao Paulo, Brazil.
Leandro Luiz Lopes de FreitasDepartment of Pathology, Universidade Estadual de Campinas (Unicamp), Sao Paulo, Brazil.
Fabiola TrainaDepartment of Medical Imaging, Hematology and Oncology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Brasil 303405/2018-0Instituto Nacional de Ciência e Tecnologia do Sangue (INCTS), Brasil 405918/2022-4São Paulo Research Foundation (FAPESP), Brasil 2017/21801-2
6 · The paper itself
Abstract
Primary myelofibrosis (PMF) is a chronic myeloproliferative neoplasm characterized by the activation of the JAK-STAT pathway. Previous evidence showed that metformin might be a possible therapeutic option for treating JAK2-mediated myeloproliferative neoplasms. In vitro and in vivo studies demonstrated that metformin inhibits the JAK-STAT pathway, induces apoptosis in JAK2
Indexed as
Bone MarrowMetforminPrimary MyelofibrosisSignal TransductionSTAT Transcription FactorsAdultAgedAnimalsDown-RegulationFemaleFibrosisHumansMaleMiceMiddle AgedMetforminSTAT Transcription FactorsFIBROMETfibrosisJAK‐STATmetforminmyelofibrosis
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.